Zomedica Corp. (AMEX:ZOM) saw a downside of -4.85% to close Tuesday at $0.18 after subtracting -$0.01 on the day. The 5-day average trading volume is 4,561,560 shares of the company’s common stock. It has gained $0.1975 in the past week and touched a new high 1 time within the past 5 days. An average of 4,216,145 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 4,397,348.
ZOM’s 1-month performance is -14.06% or -$0.0262 on its low of $0.1800 reached on 08/22/23. The company’s shares have touched a 52-week low of $0.15 and high of $0.34, with the stock’s rally to the 52-week high happening on 01/18/23. YTD, ZOM has achieved 10.61% or $0.0173 and has reached a new high 6 times. However, the current price is down -46.18% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
ZOM stock has a beta of 0.98. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 8.23 while the price-to-book (PB) in the most recent quarter is 0.69.
Zomedica Corp.’s quick ratio for the period ended June 29 was 18.90, with the current ratio over the same period at 19.40.. In terms of profitability, the gross margin trailing 12 months is 70.10%. The trailing 12-month EBITDA margin is -94.46%. The firm’s gross profit as reported stood at $13.65 million against revenue of $18.93 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -0.38% to -$5.25 million, while revenue of -$6.39 million was -21.71% off the previous quarter. Analysts expected ZOM to announce $0 per share in earnings in its latest quarter, but it posted $0. EBITDA for the quarter stood at more than -$5.87 million. ZOM stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 15.3 million, with total debt at $1.42 million. Shareholders hold equity totaling $979.95 million.
Let’s look briefly at Zomedica Corp. (ZOM) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 28.86% to suggest the stock is trending oversold, with historical volatility in this time period at 37.70%.
The stock’s 5-day moving average is $0.1886, reflecting a -8.48% or -$0.0167 change from its current price. ZOM is currently trading -11.18% above its 20-day SMA, -13.36% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -7.77% and SMA200 by-22.05%.
Stochastic %K and %D was 12.20% and 10.29% and the average true range (ATR) pointed at 0.0089. The RSI (14) points at 34.64%, while the 14-day stochastic is at 0.75% with the period’s ATR at 0.0093. The stock’s 9-day MACD Oscillator is pointing at -0.0095 and -0.0149 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Zomedica Corp. (AMEX: ZOM), Dawson James launched coverage with a Buy rating.
